Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06594965 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2024 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date: Sep 5, 2024 to Oct 30, 2024 Trial status: Recruiting to Not Yet Recruiting · Primary completion date: Sep 5, 2025 to Oct 30, 2025 · Completion date: Sep 5, 2026 to Oct 30, 2026 · 1 morev2 Show 4 more changesShow less
    • Trial status: Recruiting to Not Yet Recruiting
    • Primary completion date: Sep 5, 2025 to Oct 30, 2025
    • Completion date: Sep 5, 2026 to Oct 30, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of HS-20106 on anemia in patients with very low, low or intermediate risk MDS.
Trial Details
NCT Number NCT06594965
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Myelodysplastic Syndromes, Anemia, MDS, Bone Marrow Disease
Enrollment 176 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov